🔗 Share this article

Ministers and senior MPs have expressed alarm that the United Kingdom's negotiated accords with the US administration are "lacking a solid foundation." This follows revelations that a so-called "milestone" deal on medicines, which pledges zero tariffs in exchange for the NHS facing higher prices, lacks any formal legal text beyond broad headline terms outlined by government press releases.

A Deal Without Detail

The arrangement concerning medicines, promoted as a "generational" achievement, remains an "agreement in principle" without a signed legal text. It has been highlighted that the public statements from the UK and US governments describe the deal in markedly contrasting terms. The British version focuses on securing "duty-free access" as a singular success, while the American announcement highlights the agreement for the NHS to pay higher prices for new medications.

"There is a serious risk that the UK government has agreed to terms to increase medicine costs in return for nothing more than a verbal promise from President Trump," stated David Henig, a trade expert. "It is documented he has form for not honouring his word."

Broader Instability and a Paused Tech Deal

Worries have been heightened by Washington's action to put on ice the high-value digital accord, which was previously heralded as "a huge leap forward" in the bilateral relationship. The US pointed to a lack of progress from the UK on reducing other tariffs as the reason for the pause.

In a separate development, concessions secured for British farmers as part of an May trade agreement have still not been formally signed off by the US, despite a imminent January deadline. "Our understanding is that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

In confidential discussions, ministers have admitted unease that the government's US-UK accords are flimsy and unreliable. One minister reportedly said the series of agreements as "built on sand," while another characterized the situation as the "new normal" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, a senior MP on the health committee, remarked: "What is even more astonishing than the US approach is the UK government's credulous faith that his administration is a trustworthy negotiator. The NHS is of vital importance."

Government Downplays Risks, Points to Gains

Ministry sources have downplayed the chances of the US withdrawing from the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been lobbying for the agreement, wanting clarity on imports and pricing, making it of tangible value than the paused tech deal.

Officials concede that unpredictability is part and parcel of dealing with the Trump administration. However, they argue that the UK has secured concrete outcomes for businesses, such as preferential tariff rates compared to other nations. "Securing 25% steel tariffs, which is lower than the rate for the rest of the world, is a concrete advantage," one official said.

However, delays have emerged in implementing the May tariff agreement. Promised access for British beef have failed to be approved, and the pledge to "reduce steel tariffs to zero" has remains unmet, with tariffs fixed at 25%.

Looking ahead, the two sides have agreed to resume talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.